Stem Cells and the Study of Neurodegeneration. Tracy Young-Pearse, PhD September 12, 2014!
|
|
- Florence Norton
- 5 years ago
- Views:
Transcription
1 Stem Cells and the Study of Neurodegeneration Tracy Young-Pearse, PhD September 12, 2014!
2 Techniques for studying mechanisms of neurological disease Animal models Human subjects Postmortem analyses, imaging Induced pluripotent stem cells
3 Differential vulnerability to neurodegenerative diseases Alzheimer s disease Parkinson s disease Spinocerebellar ataxia Huntington s disease Frontotemporal dementia ALS (Lou Gehrig s disease) Narcolepsy
4 Development of stem cells from patients with Alzheimer s disease Schematic modified from Nishikawa et al, 2008
5 Overview of induced pluripotent stem cells (ipscs) Pancreatic cells Muscle cells Immune cells Neurons and glia Liver cells
6 Human ipsc neural differentiation ± mast ± dissociation D1 D5 D7 D17 D24 Media ips/es (DMEM/F12) Neural Induction (N2) Neural Induction (N2/B27) Neural Differentiation (N2/B27) +IGF, +camp +BDNF, +GDNF +IGF, +camp aggregates primi2ve NE defini2ve NE neuronal differen2a2on B ips Cells Day 4 Day 10 Day 16 Day 60
7 Differentiation of human ips cells to neuronal fates ips Cells Day 17 Day 60 Red = Oct4 = pluripotent cells Green = MAP2 = neuronal cells Blue = TOPRO3 = all cells
8 Living neurons from our patients with neurodegenerative diseases TBR1/MAP2/TOPRO3 MAP2/GFAP TAU/TOPRO3
9 Vulnerability to degeneration in Alzheimer s disease differs among brain regions Cerebral cortex and hippocampus Memory Thought Awareness Attention Consciousness Cerebellum Movement Balance Coordination Posture
10 Aβ and Tau accumulate in the cerebral cortex prior to degeneration Aβ42 aggregates Image courtesy of the Alzheimer s Association Hyperphosphorylated tau tangles
11 Mutation of APP causes early-onset Alzheimer s disease Genome editing with CRISPR/Cas to generate isogenic lines:
12 The Amyloid Hypothesis of Alzheimer s disease pathogenesis Early onset/dominantly inherited AD! ( familial )! Missense mutations in the APP or! Presenilin 1 or 2 genes! Increased Aβ42 production throughout life! Late onset AD! ( sporadic )! Failure of Aβ clearance mechanisms! (e.g., inheritance of ApoE4; faulty Aβ degradation,! environmental increases in Aβ production, etc.)! Gradually rising Aβ42 levels in brain! Accumulation and oligomerization of Aβ42! MEMORY LOSS/! Subtle effects of Aβ oligomers on synaptic efficacy! COGNITIVE DEFECTS! Microglial and astrocytic activation and attendant inflammatory responses! Altered kinase/phosphatase activities lead to tau-containing tangles! Widespread neuronal/synaptic dysfunction and selective neuronal loss,! with attendant neurotransmitter deficits! DEMENTIA!
13 APP mutation does not affect neuronal differentiation 6000 Normalized expression Normalized expression Control fad 0 MAP2 PSD-95 SYP Synapsin TuJ1 0 CTIP2 Cux1 FoxG1 GAD1 Nestin Pax6 Satb1 Six3 Sox1 Sox2 Tbr1 VGAT VGLUT1 Muratore et al, HMG, 2014
14 APP mutation leads to increased Aβ42 and Aβ38 production Aβ 42/ Aβ 42/ ctl (YZ1) ctl (YK26) fad 1a fad 1b fad 2a fad 2b 0.0 control fad ** 400 Aβ40/total protein Aβ42/total protein Aβ38/total protein ctl DMSO ctl DAPT fad DMSO fad DAPT 0 ctl DMSO ctl DAPT fad DMSO fad DAPT 0 ctl DMSO ctl DAPT fad DMSO fad DAPT Muratore et al, HMG, 2014
15 APP cleavage products increase over differentiation from immature to mature neuronal fates Aβ40/total RNA control fad Aβ42/total RNA control fad Aβ38/total RNA control fad * d9 d17 d24 d40 d60 d80 d d9 d17 d24 d40 d60 d80 d d9 d17 d24 d40 d60 d80 d100 Days of Differentiation Days of Differentiation Days of Differentiation control fad 0.5 Aβ 42/ ** d9 d17 d24 d40 d60 d80 d100 Days of Differentiation Muratore et al, HMG, 2014
16 APP mutation leads to increased β-secretase cleavage of APP * APPsα/APPsβ ** ** * ** APPα/total RNA APPsβ/total RNA ctl-yz1 ctl-yk26 fad-1a fad-1b fad-2a fad-2b 0 Control fad 0 Control fad Muratore et al, HMG, 2014
17 APP cleavage products increase over differentiation from immature to mature neuronal fates Muratore et al, HMG, 2014
18 APP subcellular localization is altered in fad ipsc-derived neurons control fad EEA-1/APP/MAP2/DAPI Muratore et al, HMG, 2014
19 The Amyloid Hypothesis of Alzheimer s disease pathogenesis Early onset/dominantly inherited AD! ( familial )! Missense mutations in the APP or! Presenilin 1 or 2 genes! Increased Aβ42 production throughout life! Late onset AD! ( sporadic )! Failure of Aβ clearance mechanisms! (e.g., inheritance of ApoE4; faulty Aβ degradation,! environmental increases in Aβ production, etc.)! Gradually rising Aβ42 levels in brain! Accumulation and oligomerization of Aβ42! MEMORY LOSS/! Subtle effects of Aβ oligomers on synaptic efficacy! COGNITIVE DEFECTS! Microglial and astrocytic activation and attendant inflammatory responses! Altered kinase/phosphatase activities lead to tau-containing tangles! Widespread neuronal/synaptic dysfunction and selective neuronal loss,! with attendant neurotransmitter deficits! DEMENTIA!
20 Higher Tau protein levels are observed in fad-derived neurons d35 d100 Muratore et al, HMG, 2014
21 Aβ-specific antibodies (3D6 and AW7) bind secreted Aβ Aβ bound to antibody: control fad Little unbound Aβ following antibody treatment: : APPs-α and β do not bind to antibody: Muratore et al, HMG, 2014
22 Aβ-specific antibodies (3D6 and AW7) rescue the Tau phenotype ELISA Total Tau/MAP2 (%Ctl) * IgG 3D6 IgG 3D6 * ELISA Total Tau/MAP2 (%Ctl) * PI AW7 PI AW7 * control fad control fad Western Blot Total Tau/MAP2 (%Ctl) * IgG 3D6 IgG 3D6 * Western Blot Total Tau/MAP2 (%Ctl) * PI AW7 PI AW7 control fad control fad Muratore et al, HMG, 2014
23 The Amyloid Hypothesis of Alzheimer s disease pathogenesis Early onset/dominantly inherited AD! ( familial )! Missense mutations in the APP or! Presenilin 1 or 2 genes! Increased Aβ42 production throughout life! Increased APPs-β and Aβ38! Late onset AD! ( sporadic )! Failure of Aβ clearance mechanisms! (e.g., inheritance of ApoE4; faulty Aβ degradation,! environmental increases in Aβ production, etc.)! Gradually rising Aβ42 levels in brain! Accumulation and oligomerization of Aβ42! MEMORY LOSS/! Subtle effects of Aβ oligomers on synaptic efficacy! COGNITIVE DEFECTS! Microglial and astrocytic activation and attendant inflammatory responses! Altered kinase/phosphatase activities lead to tau-containing tangles! Widespread neuronal/synaptic dysfunction and selective neuronal loss,! with attendant neurotransmitter deficits! DEMENTIA!
24 Examining Glial Activation in Alzheimer s Disease Muratore et al, PLOS ONE, in press
25 APPV717I induces GFAP expression in astrocytes-derived from ipscs neuronal markers astrocyte markers
26 APPV717I induces GFAP expression in human astrocytes Control neurons fad neurons Add wild type human astrocytes (Sciencell) GFAP protein levels normalized to glutamine synthetase (% control)
27 Aβ secreted from fad neurons induces GFAP expression in human astrocytes Control neuron CM fad neuron CM ctl ID Aβ ID ctl ID Aβ ID human astrocytes (Sciencell)
28 The Amyloid Hypothesis of Alzheimer s disease pathogenesis Early onset/dominantly inherited AD! ( familial )! Missense mutations in the APP or! Presenilin 1 or 2 genes! Increased Aβ42 production throughout life! Increased APPs-β and Aβ38! Late onset AD! ( sporadic )! Failure of Aβ clearance mechanisms! (e.g., inheritance of ApoE4; faulty Aβ degradation,! environmental increases in Aβ production, etc.)! Gradually rising Aβ42 levels in brain! Accumulation and oligomerization of Aβ42! MEMORY LOSS/! Subtle effects of Aβ oligomers on synaptic efficacy! COGNITIVE DEFECTS! Microglial and astrocytic activation and attendant inflammatory responses! Altered kinase/phosphatase activities lead to tau-containing tangles! Widespread neuronal/synaptic dysfunction and selective neuronal loss,! with attendant neurotransmitter deficits! DEMENTIA!
29 Differential vulnerability of neuronal subtypes in Alzheimer s disease Susceptible in AD Cortical/hippocampal forebrain neurons ipscs NPCs Cerebellar and lower motor neurons Relatively spared in AD
30 Directed differentiation of ipscs to alternate neuronal fates rostral neurons Susceptible in AD ipscs NPCs +RA/Shh caudal neurons Relatively spared in AD
31 ipscs directed to caudal neuronal fates show altered expression profiles Normalized expression Normalized expression ** ** ** ** Normalized expression * ** RA/Shh: Map2 Tuj1 Tau 0 RA/Shh: Fezf2 Tbr1 CTIP2 Reln Dab1 Six3 RA/Shh: HoxB4 HoxB6 En-1 Glra1 Irx3 MMP7
32 ipscs directed to a caudal neuronal fate secrete a less toxic ratio of Aβ42/40 Aβ/total RNA RA/Shh: 11 Aβ40 10 Aβ42 Aβ control fad Aβ 42/40 normalized to -RA/Shh for each line RA/Shh: control (YZ1) ** * * control (YK26) fad #1 fad #2 total Tau/GAPDH (% Ctl) * P-262 Tau/total Tau (% Ctl) ** ** 0 control fad control fad 0 control fad control fad +RA/Shh +RA/Shh
33 Neurons susceptible to degeneration in Alzheimer s secrete more toxic Aβ Susceptible in AD Aβ42/Aβ40 Tau Aβ42/Aβ40 ipscs NPCs Relatively spared in AD Tau
34 Measuring Aβ and sappα levels at the single cell level sappα 86,000 wells Live/Dead assay (or immunostaining, in situ, etc) Aβ Technology developed in JC Love lab (MIT) to study cytokine secretion
35 Current/Future directions: Measuring Aβ and sappα levels at the single cell level Liao et al, unpublished
36 Current/Future directions: Measuring Aβ and sappα levels at the single cell level Liao et al, unpublished
37 Summary of studies of Alzheimer s disease using ipscs 1. Generation of new stem cell (ips) lines from patients with early-onset, familial Alzheimer s disease (fad) 2. In all fates tested, the fad APP V717I mutation leads to increased total Aβ, Aβ38 and Aβ42 generation 3. Aβ generation increases as stem cells differentiate to neuronal fates 4. Tau protein levels are increased in fad neurons directed to a rostral but not caudal neuronal fate and Aβ-specific antibodies are able to rescue this phenotype 5. Aβ from fad neurons stimulates GFAP expression in astrocytes 6. Directing differentiation to caudal fates versus rostral fates alters APP cleavage 7. Microengraving can be used to determine which cell fates secrete the highest levels of Aβ, and compare drug responsiveness in different cell types
38 Young-Pearse Lab Christina Muratore, PhD Heather Rice, PhD Meichen Liao, PhD Sarah Sullivan, PhD Priya Srikanth Dana Callahan Taehwan Shin Acknowledgments Collaborators Dennis Selkoe, MD Dominic Walsh, PhD Chris Love, PhD Phil De Jager, MD David Bennett, MD
Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationDiabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian
Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes
More information9.01 Introduction to Neuroscience Fall 2007
MIT OpenCourseWare http://ocw.mit.edu 9.01 Introduction to Neuroscience Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. 9.01 Recitation (R02)
More informationSupplemental Information. Induction of Expansion and Folding. in Human Cerebral Organoids
Cell Stem Cell, Volume 20 Supplemental Information Induction of Expansion and Folding in Human Cerebral Organoids Yun Li, Julien Muffat, Attya Omer, Irene Bosch, Madeline A. Lancaster, Mriganka Sur, Lee
More informationTAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE
TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE Benoît Melchior, C. Lai, K. Duong-Polk, A. Tjitro, D.C. Ince,
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationDementia. Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
Dementia Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine What is Dementia? Dementia is a general term referring to a decline in cognitive/mental functioning; this decline
More informationTGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci
Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationNew Approach to Parkinson s Disease: Synuclein Immunotherapy
RB2014 Conference August 22, 2014 New Approach to Parkinson s Disease: Synuclein Immunotherapy Dale Schenk, PhD President and CEO Prothena Corporation plc Primary Motor and Non-Motor Symptoms of Parkinson
More informationALZHEIMER S DISEASE FACTOIDS & STATISTICS
ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10
More informationNeural progenitor cells - potent models of normal and disease neurobiology
Neural progenitor cells - potent models of normal and disease neurobiology Brian Shapiro, Ph.D. Technical Writer, Cell Biology, ATCC November 19, 2015 About ATCC Founded in 1925, ATCC is a non-profit organization
More information! slow, progressive, permanent loss of neurologic function.
UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation
More informationMicroglia, Inflammation, and FTD
FTD Minicourse April, 2009 Microglia, Inflammation, and FTD Li Gan, Ph.D Gladstone Institute of Neurological Disease University of California, San Francisco Outline Why study inflammation in neurodegeneration?
More informationLecture 42: Final Review. Martin Wessendorf, Ph.D.
Lecture 42: Final Review Martin Wessendorf, Ph.D. Lecture 33 cortex Heilbronner 5 lobes of the cortex Lateral view (left side) Mid-saggital view (right side) Cellular organization of cortex White matter
More informationTUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL)
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 28, 2017
More informationILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet July 2014, Milan, Italy
ILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet 03-04 July 2014, Milan, Italy Flavonoids as modulators of APP Processing: A Dietary intervention for
More informationSUPPLEMENTARY INFORMATION
DOI: 10.1038/ncb2566 Figure S1 CDKL5 protein expression pattern and localization in mouse brain. (a) Multiple-tissue western blot from a postnatal day (P) 21 mouse probed with an antibody against CDKL5.
More informationTau Mechanism in Dementia
ADC Directors Meeting Saturday, April 12, 2008 Sheraton V Tau Mechanism in Dementia Lennart Mucke, M.D. Director, Gladstone Institute of Neurological Disease Joseph B. Martin Distinguished Professor Department
More informationPrimary Mouse Cerebral Cortex Neurons V: 80% TE: 70%
Primary Mouse Cerebral Cortex Neurons V: 80% TE: 70% Pictures: 9 days after electroporation Red: MAP2 Blue: GFAP Green: GFP The cells were from Embryonic Day 14 Mouse Cerebral Cortex Primary Mouse Hippocampal
More informationTAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE
TAU PATHOLOGY REDUCTION WITH SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRKA INHIBITOR - A POTENTIAL THERAPEUTIC FOR ALZHEIMER S DISEASE Benoît Melchior, Carolyn Lai, Karen Duong-Polk, Amanda Tjitro,
More informationMemory Disorders. 1. Episodic: memory for time and places. 2. Semantic: memory for facts and knowledge (language, numbers, etc).
I. Types of memory: A. Declarative memory: Memory Disorders 1. Episodic: memory for time and places. 2. Semantic: memory for facts and knowledge (language, numbers, etc). B. Procedural memory: - examples:
More informationDevelopment of the Nervous System. Leah Militello, class of 2018
Development of the Nervous System Leah Militello, class of 2018 Learning Objectives 1. Describe the formation and fate of the neural tube and neural crest including timing and germ layer involved. 2. Describe
More informationNeurodevelopment II Structure Formation. Reading: BCP Chapter 23
Neurodevelopment II Structure Formation Reading: BCP Chapter 23 Phases of Development Ovum + Sperm = Zygote Cell division (multiplication) Neurogenesis Induction of the neural plate Neural proliferation
More informationChapter 18 Genetics of Behavior. Chapter 18 Human Heredity by Michael Cummings 2006 Brooks/Cole-Thomson Learning
Chapter 18 Genetics of Behavior Behavior Most human behaviors are polygenic and have significant environmental influences Methods used to study inheritance include Classical methods of linkage and pedigree
More informationCSF: Lessons From Other Diseases
CSF: Lessons From Other Diseases Consultant: AbbVie, Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, Teva Research: Actelion, Novartis, Opexa Alzheimer s Progressive
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationIn vivo reprogramming reactive glia into ipscs to produce new neurons in the
In vivo reprogramming reactive glia into ipscs to produce new neurons in the cortex following traumatic brain injury Xiang Gao 1, Xiaoting Wang 1, Wenhui Xiong 1, Jinhui Chen 1, * 1 Spinal Cord and Brain
More informationStrategies for Neurorestoration: Growth Factors
Strategies for Neurorestoration: Growth Factors Elena Posse de Chaves, PhD 928-MSB Phone: 492-5966 Email: elena.chaves@ualberta.ca Treatment of Neurodegenerative Diseases Most neurodegenerative diseases
More informationAnalysis of Chlamydia Pneumoniae and AD-like Pathology in the Brains of BALB/c Mice Following Direct Intracranial Infection with Chlamydia Pneumoniae
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Biomedical Studies Student Scholarship Student Dissertations, Theses and Papers 8-2011 Analysis of Chlamydia Pneumoniae and AD-like
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationNeuropathology of Neurodegenerative Disorders Prof. Jillian Kril
Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration
More informationNeuroinflammation in preclinical AD: in vivo evidence
Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of
More informationNeurodegenerative disorders and diabetes: common underlying impairments. N.M. Lalic (Serbia)
Neurodegenerative disorders and diabetes: common underlying impairments N.M. Lalic (Serbia) Neurodegenerative disorders and diabetes: common underlying impairments Professor Nebojsa M. Lalic Faculty of
More informationNature Neuroscience: doi: /nn Supplementary Figure 1. PICALM expression in brain capillary endothelium in human brain and in mouse brain.
Supplementary Figure 1 PICALM expression in brain capillary endothelium in human brain and in mouse brain. a, Double immunostaining for PICALM (red, left) and lectin positive endothelial profiles (blue,
More informationCorporate Medical Policy Genetic Testing for Alzheimer s Disease
Corporate Medical Policy Genetic Testing for Alzheimer s Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alzheimers_disease 8/2010 10/2017 10/2018 10/2017
More informationGENETICS Can we Really Blame it all on Our Genes?
GENETICS Can we Really Blame it all on Our Genes? Lecture 3: Understanding the Genetics of some Common Diseases and Disorders Thursday, May 12th, 2016 Medical Sciences Building 150 Jane Gair, Ph. D. Upcoming
More informationNeuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU
Neuroprotective properties of GLP-1 - a brief overview Michael Gejl Jensen, MD Dept. Of Pharmacology, AU mg@farm.au.dk Agenda Glucagon-like peptide (GLP-1) GLP-1 and neuronal activity GLP-1 in disease-specific
More informationSelective filtering defect at the axon initial segment in Alzheimer s disease mouse models. Yu Wu
Selective filtering defect at the axon initial segment in Alzheimer s disease mouse models Yu Wu Alzheimer s Disease (AD) Mouse models: APP/PS1, PS1δE9, APPswe, hps1 Wirths, O. et al, Acta neuropathologica
More informationShift 1, 8 July 2018, 09:30-13:00
Shift 1, 8 July 2018, 09:30-13:00 CNS patterning A001-A014 Stem cells: basic biology and postnatal neurogenesis - part I Development of neural systems: Molecular and genetic characterisationa Epigenetic
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses Yichen Shi 1,2, Peter Kirwan 1,2, James Smith 1,2, Hugh P.C. Robinson 3 and Frederick
More informationA new approach to Common Sporadic Alzheimer s, Post-Traumatic Alzheimer s, and CTE:
A new approach to Common Sporadic Alzheimer s, Post-Traumatic Alzheimer s, and CTE: Roles of Aβ, Tau, ApoE, and Regulatory Signaling in Elucidating Pathogenesis and Experimental Therapeutics Sam Gandy,
More informationDiscordance for exposures and disease phenotypes
Discordance for exposures and disease phenotypes To what extent can easilyaccessible peripheral tissues/cells (e.g. whole blood, saliva, buccal) be used as a proxy for inaccessible tissues/cells? UK Brain
More informationThe Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina
The Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina Pathology in the Cerebral Cortex H&E stain of mature neuritic plaque Modified Bielschowsky stain
More informationClinical Genetics & Dementia
Clinical Genetics & Dementia Dr Nayana Lahiri Consultant in Clinical Genetics & Honorary Senior Lecturer Nayana.lahiri@nhs.net Aims of the Session To appreciate the potential utility of family history
More informationRole of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
More informationMary ET Boyle, Ph. D. Department of Cognitive Science UCSD
? Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Christian S Lobsiger & Don W Cleveland (2007) Nature Neuroscience 10, 1355-1360 Astrocytes: interlinked gatekeepers of glutamate astrocytes
More informationNeurogenesis in Adult Central Nervous System: Death of a Dogma
Aristotle University of Thessaloniki, Greece, Nov. 2007 Neurogenesis in Adult Central Nervous System: Death of a Dogma Anton B. Tonchev Division of Cell Biology, Varna University of Medicine, Bulgaria
More informationSupplementary Figure S1. Monolayer differentiation of mouse ESCs into telencephalic neural precursors. (a) Schematic representation of the protocols
Supplementary Figure S1. Monolayer differentiation of mouse ESCs into telencephalic neural precursors. (a) Schematic representation of the protocols used to differentiate mouse ESCs. (b) Representative
More informationContents. Introduction. Introduction 03
Genes and dementia Introduction This information is for anyone who wants to know more about the link between genes and dementia. This includes people living with dementia, their carers, friends and families.
More informationINTRODUCTION TO NEUROLOGICAL DISEASE Learning in Retirement Session #6 Alzheimer disease
INTRODUCTION TO NEUROLOGICAL DISEASE Learning in Retirement Session #6 Alzheimer disease Lesson Overview Normal Aging VS Dementia What is Alzheimer disease? AD Pathology General Cellular Molecular Prognosis
More informationDelirium, Apo-E status, and AD CSF biomarkers
Delirium, Apo-E status, and AD CSF biomarkers Zhongcong Xie, M.D., Ph.D. Geriatric Anesthesia Research Unit Department of Anesthesia, Critical Care and Pain Medicine Massachusetts General Hospital Harvard
More informationHuman Neurology 3-Plex A
Human Neurology 3-Plex A SUMMARY AND EXPLANATION OF THE TEST The Human N3PA assay is a digital immunoassay for the quantitative determination of total Tau, Aβ42, and Aβ40 in human plasma and CSF. Determination
More informationThe Spectrum of Age-Associated Astroglial Tauopathies. Dennis W. Dickson MD Department of Neuroscience Mayo Clinic, Jacksonville, FL
The Spectrum of Age-Associated Astroglial Tauopathies Dennis W. Dickson MD Mayo Clinic, Jacksonville, FL Thorn-shaped astrocytes TSA were first reported by Ikeda (1995), as tau-positive astrocytes in various
More informationThe role of the vascular system in dementia
The role of the vascular system in dementia James AR Nicoll Professor of Neuropathology, University of Southampton Consultant Neuropathologist, Southampton General Hospital What does the vascular system
More informationLDLR-related protein 10 (LRP10) regulates amyloid precursor protein (APP) trafficking and processing: evidence for a role in Alzheimer s disease
Brodeur et al. Molecular Neurodegeneration 2012, 7:31 RESEARCH ARTICLE Open Access LDLR-related protein 10 (LRP10) regulates amyloid precursor protein (APP) trafficking and processing: evidence for a role
More informationLowering the risk for Alzheimer s Disease Intake: Nutrition & AD. pspilman2015
Lowering the risk for Alzheimer s Disease Intake: Nutrition & AD 1 The Hippocampus Hippocampal & cortical brain regions are affected in AD. 2 The Neuron Neurons lose connections (synapses) Branches (dendrites)
More informationAmyloid β Degradation & Inflammation: New Therapeutic Strategies in AD. Li Gan, Ph.D
ADC Directors Meeting Chicago, April 12, 2008 Amyloid β Degradation & Inflammation: New Therapeutic Strategies in AD Li Gan, Ph.D Gladstone Institute of Neurological Disease University of California, San
More informationTheme Topics Subtopics. Basic and Translational Science. Development of New Models and Analysis Methods
Basic and Translational Science Development of New Models and Analysis Methods α-synuclein Amyloid/Abeta Behavioral models Inflammation Novel assays and technologies Screening studies/platforms Seeding
More informationSynaptic changes in dementia: links to cognition and behaviour
Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research Agenda Discuss synaptic changes in various dementias
More informationWhat s happening in the Research World of Down syndrome? Overview of research in Down Syndrome: Guided by the NIH Down Syndrome Research Plan
What s happening in the Research World of Down syndrome? Overview of research in Down Syndrome: Guided by the NIH Down Syndrome Research Plan What is our common goal? Increase quality of life of those
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationTreatment of Neurological Disorders. David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018
Treatment of Neurological Disorders David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018 1 Corporate Overview Developing first-in-class therapies to treat orphan and non-orphan
More informationPhD DIMET. Anti-amyloidogenic activity of a mutant form of Aβ: a new strategy for Alzheimer therapy
PhD PROGRAM IN TRANSLATIONAL AND MOLECULAR MEDICINE DIMET UNIVERSITY OF MILANO-BICOCCA SCHOOL OF MEDICINE AND FACULTY OF SCIENCE Anti-amyloidogenic activity of a mutant form of Aβ: a new strategy for Alzheimer
More informationCASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?
CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationFor personal use only. Annual General Meeting 13 November 2015
Annual General Meeting 13 November 2015 This presentation may contain some statements that may be considered Forward-Looking Statements, within the meaning of the US Securities Laws. Thus, any forward-looking
More informationDISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a
More informationCephalization. Nervous Systems Chapter 49 11/10/2013. Nervous systems consist of circuits of neurons and supporting cells
Nervous Systems Chapter 49 Cephalization Nervous systems consist of circuits of neurons and supporting cells Nervous system organization usually correlates with lifestyle Organization of the vertebrate
More informationFunctional Development of Neuronal Networks in Culture -An in vitro Assay System of Developing Brain for Endocrine Disruptors
Functional Development of Neuronal Networks in Culture -An in vitro Assay System of Developing Brain for Endocrine Disruptors Masahiro Kawahara and Yoichiro Kuroda Tokyo Metropolitan Institute for Neuroscience
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More information212 Index C-SB-13,
Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration
More informationInstitute of Molecular and Cellular Biology FACULTY OF BIOLOGICAL SCIENCES. Lipid rafts in neurodegenerative diseases. Nigel M.
Institute of Molecular and Cellular Biology FACULTY OF BIOLOGICAL SCIENCES Lipid rafts in neurodegenerative diseases Nigel M. Hooper Institute of Molecular and Cellular Biology FACULTY OF BIOLOGICAL SCIENCES
More informationRecent Findings from Analysis of HIV Clade C in India
Recent Findings from Analysis of HIV Clade C in India Pankaj Seth, Ph.D Associate Professor, Molecular & Cellular Neuroscience National Brain Research Centre (NBRC) Manesar, INDIA pseth@nbrc.res.in NeuroAIDS
More informationCHARACTERIZATION OF PROTEINS INVOLVED IN THE PRODUCTION OF β-amyloid PEPTIDES AND TAU HYPERPHOSPHORYLATION IN FAMILIAL ALZHEIMER S DISEASE
CHARACTERIZATION OF PROTEINS INVOLVED IN THE PRODUCTION OF β-amyloid PEPTIDES AND TAU HYPERPHOSPHORYLATION IN FAMILIAL ALZHEIMER S DISEASE DISSERTATION Submitted to the Department of Biology Faculty of
More informationCONTRACTING ORGANIZATION: Rutgers, the State University of New Jersey New Brunswick, NJ 08901
AWARD NUMBER: W81XWH-16-1-0415 TITLE: Cell Type-Specific Contributions to the TSC Neuropathology PRINCIPAL INVESTIGATOR: Gabriella D Arcangelo CONTRACTING ORGANIZATION: Rutgers, the State University of
More informationStudy Guide Unit 2 Psych 2022, Fall 2003
Study Guide Unit 2 Psych 2022, Fall 2003 Subcortical Anatomy 1. Be able to locate the following structures and be able to indicate whether they are located in the forebrain, diencephalon, midbrain, pons,
More informationSleep Cycle Shift and its effects on Cognitive Function
Sleep Cycle Shift and its effects on Cognitive Function MARY ET BOYLE, PH. D. DEPARTMENT OF COGNITIVE SCIENCE UCSD Sleep wake cycle is regulated by the circadian system. Superchiasmatic Nucleus in the
More informationFDG-PET e parkinsonismi
Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism
More informationGenetics of neurological disorders
Review Genetics of neurological disorders Mohammad Ali Faghihi, Salim Mottagui-Tabar and Claes Wahlestedt CONTENTS Alzheimer s disease Frontotemporal dementia & Pick s disease Normal pressure hydrocephalus
More informationMULTIPLE CONCUSSIONS LEAD TO CHRONIC TRAUMATIC ENCEPHALOPATHY (CTE)
MULTIPLE CONCUSSIONS LEAD TO CHRONIC TRAUMATIC ENCEPHALOPATHY (CTE) CTE may develop within a short time of trauma but usually years intervene Symptoms Cognitive: depression, dementia Movement disorders:
More informationCommon Versus Uncommon Causes of Dementia
Edith Cowan University Research Online ECU Publications Pre. 2011 2005 Common Versus Uncommon Causes of Dementia Nicola Lautenschlager University of Western Australia Ralph Martins Edith Cowan University
More informationEast of England Neurology Training Fellowships 2016
East of England Neurology Training Fellowships 2016 Neurology training in the East of England deanery is the only neurology training scheme in the UK focused on training in academic neurology. All trainees
More informationGenesis of cerebellar interneurons and the prevention of neural DNA damage require XRCC1.
Genesis of cerebellar interneurons and the prevention of neural DNA damage require XRCC1. Youngsoo Lee, Sachin Katyal, Yang Li, Sherif F. El-Khamisy, Helen R. Russell, Keith W. Caldecott and Peter J. McKinnon.
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationParis: Diabetes, Insulin, and Alzheimer Disease
Paris: Diabetes, Insulin, and Alzheimer Disease Adapted from an original article by Jennifer Altman in Alzheimer Actualités, a newsletter published in French by the Ipsen Foundation. The Alzforum acknowledges
More informationDelirium & Dementia. Nicholas J. Silvestri, MD
Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts
More informationInsulin and Neurodegenerative Diseases: Shared and Specific Mechanisms. Cogs 163 Stella Ng Wendy Vega
Insulin and Neurodegenerative Diseases: Shared and Specific Mechanisms Cogs 163 Stella Ng Wendy Vega Overview A. Insulin and the Brain B. Alzheimer s Disease and Insulin C. Other neurodegenerative disease:
More informationFig. 4. The activity of Pkc -transduced neurons is required for enhanced learning. After gene transfer, rats were tested on [] vs. +.
Research Interests Advanced cognitive learning is encoded in distributed circuits that span multiple forebrain areas. Further, synaptic plasticity and neural network theories hypothesize that essential
More informationB-cell. Astrocyte SCI SCI. T-cell
RF #2015 P-01 PI: Azizul Haque, PhD Grant Title: Targeting Enolase in Spinal Cord Injury 12-month Technical Progress Report Progress Report (First Six Months): Enolase is one of the most abundantly expressed
More informationCell Migration II: CNS Cell Migration. Steven McLoon Department of Neuroscience University of Minnesota
Cell Migration II: CNS Cell Migration Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Coffee Hour Wednesday (Oct 18) 9:00-10:00am Surdyk s Café in Northrop Auditorium Stop
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationTAKEDA NEUROSCIENCE BRINGING INNOVATIVE MEDICINES TO PATIENTS FOR WHOM THERE ARE NO TREATMENTS AVAILABLE
TAKEDA NEUROSCIENCE BRINGING INNOVATIVE MEDICINES TO PATIENTS FOR WHOM THERE ARE NO TREATMENTS AVAILABLE EMILIANGELO RATTI, PHD Head, Neuroscience Therapeutic Area WE HAVE TAKEN ON THE CHALLENGE TO ALLEVIATE
More informationPRIMER. Alzheimer s disease
Alzheimer s disease Colin L. Masters 1, Randall Bateman 2, Kaj Blennow 3, Christopher C. Rowe 4, Reisa A. Sperling 5,6 and Jeffrey L. Cummings 7 Abstract Alzheimer s disease is a chronic illness with long
More informationWhat is Neuropsychology?
Alzheimer s Disease Neurological Bases and Informed Behavioral Interventions Peter T. Keenan Clinical Neuropsychologist Marshfield Clinic Minocqua Center What is Neuropsychology? Science of the relationship
More information